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Abstract
Postoperative bleeding might become a serious problem in the management of cardiac surgical
patients, with marked medical and economic impact. In these life-threatening situations, massive
haemorrhage represents frequently a combination of surgical and coagulopathic bleeding. Surgical
bleeding results from a definite source at the operation site and can be corrected using surgical
standard techniques. Acute coagulopathies, in contrast, result from impaired thrombin formation,
and require optimized therapeutical strategies. Effective pharmacological treatment will be
complicated by the presence of ventricular assist devices (VAD), which necessarily imply effective
anticoagulation.
In episodes of uncontrolled coagulopathic bleeding, the application of recombinant activated factor
VII (rFVIIa) as a effective haemostatic agent has become more and more popular. However, only
very few data are available on its use in patients with VAD in place.
We researched the PubMed-database for case reports about the use of rFVIIa in patients with VAD
and summarized them. In addition, we report a case from our hospital. In all cases cessation of
bleeding without any thrombembolic complications could be achieved. In cases of uncontrollable,
non-surgical bleeding rFVIIa seems to be a therapeutical option even for patients with VAD.
Introduction
Over the last decade, the impact of ventricular assist
devices (VAD) in the treatment of end-stage cardiac failure
has been increasingly recognized. Next to elective "bridge-
to-transplant"-implantation, VAD are frequently used
during cardiac surgery procedures if weaning from cardi-
opulmonary bypass is refractory due to poor cardiac per-
formance. Out of 115 VAD inserted during a six-year-
period at a major tertiary referral centre in New York for
example, 63% were non-elective [1]. While using these
devices, however, the risk of major non-surgical bleeding
is high, especially during and early after cardiac surgery, as
VAD require an efficient anticoagulation because of their
thrombogenic surface [2].
Massive postoperative haemorrhage is frequently a com-
bination of surgical and coagulopathic bleeding. Surgical
bleeding results from a definite source at the operation
site and can be corrected using traditional surgical tech-
niques (e.g., ligation of vessels, cauterization, etc.). In
contrast, acute coagulopathies result from impaired
thrombin formation, develop early after surgical trauma,
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and thus may seriously complicate these life-threatening
situations. For several years, rFVIIa (NovoSeven®) has
been approved for haemophilic patients with inhibitors.
However, in episodes of uncontrolled postoperative
bleeding, the off-label use of rFVIIa as a potentially effec-
tive, but cost-intensive haemostatic agent has been rapidly
expanding. rFVIIa links with tissue factor, which is
released from injured tissue, and then activates factor IX
and X, respectively. Subsequently, the formation of fibrin
is initiated. In addition, supra-normal concentrations of
FVIIa lead to an increased thrombin synthesis in platelets
as well as to an activation of cellular haemostasis [3].
Especially in patients with VAD and uncontrolled non-
surgical bleeding, the application of rFVIIa is a therapeuti-
cal challenge as thrombembolic complications may lead
to severe dysfunctions of these devices.
In this article, we report the application of rFVIIa in a
patient with a biventricular assist device (BIVAD) in order
to treat massive non-surgical bleeding, and present a
review on the current literature.
Case report
A 22 year old man with a history of congenital dilatative
cardiomyopathy (left ventricular ejection fraction < 20%)
was admitted to the medical ICU after acute cardiac
decompensation. Despite the application of inotropics at
maximum doses (incluiding levosimendan), it was not
possible to restore an adequate cardiac performance, and
subsequently, even mechanical cardiopulmonary resusci-
tation had to be started. As an ultima ratio procedure,
emergency thoracotomy was immediately performed, the
patient was heparinized (300 I.U./kg) and rapidly con-
nected to extracorporal circulation. After implantation of
a left ventricular assist device (LVAD) and reperfusion,
weaning from cardiopulmonary bypass failed due to an
acute right ventricular failure. Consequently, a right-ven-
tricular assist device (RVAD) was additionally implanted,
and extracorporal circulation could be stopped without
complications.
After this emergency procedure, the patient was trans-
ferred to the surgical ICU in stable haemodynamic condi-
tions. However, the patient was continuously and
massively bleeding, with a blood loss of > 500 mL per 15
minutes. It was necessary transfuse 10 units of red blood
cells (RBC), 7 units of frozen plasma (FFP) and 10 units
of platelet concentrate (PC), and to substitute 3000 I.U. of
prothrombin complex (PPSB), 3000 I.U. of antithrombin
and 6 g of fibrinogen immediately after arrival on the ICU.
Despite these efforts, massive blood loss persisted and a
re-thoracotomy was performed at the bedside. During this
procedure, surgical reasons for the haemorrhage at the site
of surgery could be definitely excluded. After this proce-
dure again 10 units of RBC, 14 units of FFP, 7500 I.U. of
PPSB and 7000 I.U. of protamine were given without any
significant effect. Laboratory values showed a clearly
impaired coagulation (PT 44%, PTT 88 sec., ACT 229 sec.,
fibrinogen 124 g/dl, platelets 59 × 103/µL). In situation,
we decided to apply rFVIIa, and after a single dose of 120
µg/kg, bleeding stopped within a few minutes. Fortu-
nately, the function of the VAD remained completely
unimpaired.
In the further course, however, the patient developed
acute renal failure, and increasing doses of norepine-
phrine and finally vasopressin were necessary in order to
maintain an adequate perfusion pressure. Liver enzymes
massively increased, and furthermore, extracorporal
membrane oxygenation had to be initiated due to the
rapid development of severe lung failure. 9 days after the
implantation of the VAD a fixed bilateral mydriasis
became apparent, and clinical examination revealed the
complete absence of brain stem reflexes. Subsequently, a
transcranial Doppler examination was performed, which
revealed a complete stop of cerebral perfusion. This exam-
ination was repeated after twelve hours and confirmed the
absence of cerebral blood flow. Based on these findings,
the decision was made to stop any therapeutical efforts,
and VADs were switched off leading to an immediate cir-
culatory arrest.
Review of the literature
To our knowledge, four cases have been published so far
referring to the therapy with rFVIIa in patients with VAD.
Flynn and co-workers report on a 44 years old male
patient who suffered from an ischemic cardiomyopathy
and received a LVAD because of chronic deterioration of
his cardiac performance. [4] As several weaning attempts
failed, the temporary VAD was switched to a permanent
device ("artificial heart") using cardiopulmonary bypass.
Despite the fact that activated clotting time (ACT) after
reversal of heparin was <150 sec, a diffuse haemorrhage
exceeding 1500 mL/h from all chest tubes occurred. After
the substitution of 11 units of FFP, 7 units of PC and PPSB
(in an unknown dose) the bleeding still continued.
Hence, rFVIIa was administered in a single dose of 90 µg/
kg, and blood loss immediately decreased below 100 mL/
h. The following postoperative course was uncompli-
cated, the patient was listed for heart transplantation and
discharged from hospital with the permanent assist
device.
In a case report of Kogan et al., a 48 years old male patient
underwent heart transplantation due to severe ischemic
cardiomyopathy [5]. After aortic declamping, an episode
of a electromechanical dissociation occurred without a
perceptible reason. Adequate left ventricular performance
could only be restored applying high doses of catecho-Journal of Cardiothoracic Surgery 2007, 2:47 http://www.cardiothoracicsurgery.org/content/2/1/47
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lamines (25 µg/kg/min dobutamine, 0,8 µg/kg/min
epinephrine and 4,2 µg/kg/min norepinephrine, respec-
tively) and inserting an intraaortic counterpulsation
pump. As the right ventricle remained akinetic, it was nec-
essary to implant a RVAD. After a total bypass time of
more than 9 hours, a diffuse and massive haemorrhage
became evident and persisted despite the administration
of 20 units of RBC, 15 units of FFP and 16 units of PC. In
this situation, laboratory investigations revealed an
impaired coagulation (INR 2,86, PTT > 120 sec., fibrino-
gen 115 mg/dl, platelets 78.000/µl). After application of
two doses of rFVIIa (2 × 35 µg/kg, in an interval of 60 min-
utes) the bleeding suspended, and the patient could be
transferred to the surgical ICU. In the following, right ven-
tricular function slowly recovered, and the application of
nitric oxide (NO) finally led to a complete recompensa-
tion within 24 hours. The patient was discharged from
hospital on the 19. postoperative day.
In another publication, Potapov and co-workers report on
a 57 years old woman with acute myocarditis and severe
cardiogenic shock [6]. Despite of a high-dose therapy with
catecholamines (1 µg/kg/min epinephrine, 7 µg/kg/min
dobutamine, 0,7 µg/kg/min norepinephrine), low cardiac
output persisted. To maintain adequate systemic per-
fusion a biventricular assist device (BIVAD) was
implanted. Postoperatively, a massive blood loss of more
than 1000 mL/h required the transfusion of 30 units of
RBC. In an attempt to optimize coagulation, a total of 56
units of FFP, 4 units of PC, 2000 I.U. of PPSB, 28 µg
desmopressine, protamine and aprotinine (unknown
doses) were administered. Nevertheless, the bleeding per-
sisted despite a apparently normal coagulation status
(INR 1,39, PTT 42,5 sec., fibrinogen 212 g/dl, AT 83%).
12 hours postoperatively, a single dose of 120 µg/kg
rFVIIa was given, and blood loss immediately decreased
to < 500 mL/h. Two hours later, a second dose of 60 µg/
kg rFVIIa (and two units of PC) were applied, and the
bleeding rate further decreased to <100 mL/h. The func-
tion of the BIVAD was not affected, especially no throm-
boembolic complications were encountered. However,
the patient's outcome remains unclear in this case report.
Zietkiewicz et al. report on a 34 years old man undergoing
elective replacement of a mitral valve prosthesis [7]. Two
operations – a mitral valve anuloplasty as well as a tricus-
pid anuloplasty with the initial replacement of the mitral
valve – preceded this procedure. Postoperatively, the
patient developed a severe cardiogenic shock refractory to
high doses of inotropes (no further data applicable). In
order to relief the impaired left ventricle and to maintain
adequate organ perfusion, a LVAD was implanted. Within
the first 6 postoperative hours, diffuse bleedings of >1000
mL/h from chest tubes, wounds and from the nose
occurred. RBC, FFP, PC and tranexamic acid were admin-
istered (doses not applicable). Nevertheless, massive
blood loss persisted in spite of the fact that laboratory
parameters for coagulation were nearly unaffected (INR
1,61, AT 62%, fibrinogen 271 mg/dL, platelets 89.000/
µl). In the following, the patient received 20 µg/kg rFVIIa,
and during the next two hours, the haemorrhage
decreased to 25 mL/h. However, as blood loss increased
again 4 hours later, a a second dose of 30 µg/kg rFVIIa was
given which led to complete cessation of the bleeding.
Again, the function of the LVAD was not impaired at all.
Unfortunately, 7 days later, an acute tension pneumotho-
rax caused an acute cardiac decompensation. Despite the
immediate initiation of chest drains, cardiac performance
was refractory to pharmacological treatment, and the
patient died.
In our case, where finally clinical and ultrasound doppler
signs of brain death were obsereved we can, even if it
seems unlikely, not definitievly exclude that a thro-
mobembolic complication caused massive ischemic cere-
bral infarction followed by massive brain edema,
resulting in a stop of cerebral perfusion.
Discussion
Transfusion of autologous blood products is not only
cost-intensive, but implies also the risk of several serious
adverse events. Many clinical studies clearly document the
direct inter-relation between the number of transfused
units and the incidence of nosocomial infections, the
duration of hospital stay, the number of ventilator days,
mortality, the incidence of acute renal failure and cardiac
complications, respectively [8-11]. Thus, the perioperative
reduction of blood products appears to be a very impor-
tant strategy which should start with the preoperative
identification of patients at risk of massive blood loss. In
cardiac surgery, for example, the risk of bleeding is signif-
icantly elevated when anticoagulation is performed with
hirudine [12], in the presence of septic endocarditis [13]
or hepatic disorders [14], after preoperative administra-
tion of platelet aggregation inhibitors [15], re-operations
[16] and emergency procedures, respectively [17]. In this
respect, the adequate management of patients undergoing
VAD implantation represents a particular challenge to the
physicians involved, as permanent cannulation of large
vessels as well as the obligatory anticoagulation both tre-
mendously increase the risk of postoperative haemor-
rhage [2].
Even if the treatment of non-haemophilic patients with
rFVIIa represents an "off label" use, this agent is known to
be an effective haemostatic agent in uncontrolled haemor-
rhage caused by a wide spectrum of clinical scenarios [18].
Especially after cardiac surgery, it is a well-known fact that
even massive bleedings following anticoagulation with
lepirudine may sufficiently be treated with rFVIIa [19].Journal of Cardiothoracic Surgery 2007, 2:47 http://www.cardiothoracicsurgery.org/content/2/1/47
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The effect of rFVIIa on plasmatic coagulation derives from
its interaction with tissue factor. Thus, the pro-coagulatory
effect is predominantly located in regions where tissues or
vessels are injured [3]. This intriguing characteristic might
be an explanation for the relatively low incidence of
thrombembolic events (1–2%) after the use of rFVIIa [20].
Marson and co-workers even treated a patient with rFVIIa
who preoperatively suffered from repeated deep venous
thromboses and who therefore had placed a filter within
the inferior caval vein. However, no thrombembolic com-
plications were encountered [21]. Recently, O'Connell et
al. published a detailed analysis of 431 „adverse event
reports” in conjunction with the use of rFVIIa. [22]. 168 of
these voluntary declarations referred to thrombembolic
complications – „assist devices” (in a broader sense,
including dialysis shunts and even endotracheal tubes
etc.) were affected in only 10 cases. In this respect,
thrombembolic complications in patients with VAD were
not explicitly mentioned, and thus seem to be very rare.
Nevertheless, the authors point out that these reports were
voluntary, and thus, their analysis probably underesti-
mates the absolute number of complications after appli-
cation of rFVIIa.
In 2005, Von Heymann and co-workers published their
experiences with 26 patients who were successfully treated
with rFVIIa after cardiac surgery without any thrombem-
bolic complications. Interestingly, three of these patients
were in need of a VAD.
The reviewed cases clearly suggest that the exact timing of
the treatment with rFVIIa plays an important role. In this
respect, an untimely administration seems to be as disad-
vantageous as a delayed therapy, as additional costs and
an increased risk of further blood transfusions may be
caused. Using pharmaco-economic criteria, Loudon and
Smith determined the optimal time point for the applica-
tion of rFVIIa after transfusion of 14 units of red blood
cells [23]. Restrictively, they point out that this is the result
of a theoretical analysis which implies the prompt cessa-
tion of bleedings directly after therapy with rFVIIa. How-
ever, another analysis of 50 patients treated with rFVIIa
concludes that delayed application of rFVIIa worsens the
patient's prognosis [24].
As mentioned above, in O'Connell's analysis of 431 vol-
untarily reported complications after the use of rFVIIa,
only 10 concerned thrombembolic episodes associated
with „assist devices” [22]. In spite of the fact that these
data suggest that thrombembolism in VAD patients is a
very rare complication after the use of rFVIIa, it may cause
life-threatening dysfunctions, and hence, the seriousness
of such events should not be underestimated. Neverthe-
less, in 36 of 50 lethal complications, the most probable
cause of death was embolism, for example in pulmonary
or coronary arteries. Thus, independent of the presence or
absence of VAD, these data suggest that the application of
rFVIIa generally implies the risk of serious thrombembolic
complications.
Conclusion
In this article, we report about the successful application
of rFVIIa in a patient with biventricular assist device
(BIVAD) in order to treat massive non-surgical bleeding,
and give a brief review on the current literature. We con-
clude that in a uncontrolled non-surgical haemorrhage,
the administration of rFVIIa seems to be a promising ther-
apeutic option even in patients with VAD, especially when
„conventional” treatment (substitution of coagulation
factors or platelets, desmopressine, antifibrinolytics) is
not effective. In this respect, the exact timing for starting
the treatment with rFVIIa is important in order to mini-
mize the risks of mass transfusion. Nevertheless, rFVIIa
therapy in patients with VAD requires meticulous moni-
toring, with special regard to thrombembolic events. In
addition, the repeated application of small doses (e.g. 30–
40 µg/kg), if necessary, might, under these circumstances,
be an effective and cost saving procedure.
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Table 1: Summary of previously published case reports about the use of rFVIIa in patients with ventricular assist devices
Flynn et al., [4] Kogan et al., [5] Potapov et al., [6] Zietkiewicz et al., [7]
Type of VAD LVAD RVAD BIVAD LVAD
Blood loss before rFVIIa 1500 mL/h Massive bleeding 1000 mL/h 1000 mL/h
Therapy before administration of 
rFVIIa
11 FFP 7 PC. PPSB* 15 FFP 16 PC. (20 units RBC) 56 FFP 4 PC. 2000 i.U. PPSB 28 µg 
desmopressine protamine* 
aprotinine* (30 units RBC)
FFP* PC* tranexamic acid* (RBC)*
Laboratory values before 
administration of rFVIIa
not reported INR: 2,86 PTT: > 120 sec. Fib.: 115 
mg/dl PLT.: 78.000/µL
INR: 1,39 PTT: 42,5 sec. Fib.: 212 
mg/dl AT: 83% PLT.: 54.800/µL
INR: 1,61 AT: 62% Fib.: 271 mg/dL 
PLTr.: 89.000/µL
Dose of rFVIIa 90 µg/kg 2 × 35 µg/kg 120 + 60 µg/kg 20 + 30 µg/kg
Blood loss after rFVIIa < 100 mL/h 0 < 100 mL/h < 15 mL/h
Laboratory values after 
administration of rFVIIa
not reported INR: 1,3 PTT: 34 sec. Fib.: 127 mg/dL 
PLT.: 88.000/µl
INR: 1,19 PTT: 47 sec. Fib.: 144 mg/
dL AT: 52% PLT.: 75.700/µL
INR: 0,89
Clinical course/outcome Discharged from hospital 
with permanent LVAD, 
listed for heart 
transplantation
Recompensation, explantation of 
RVAD, discharged from hospital
No thromboembolic complications. 
Outcome not reported.
No thromboembolic complications. 
Lethal tension pneumothorax 7 days 
after implantation of VAD.
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